PMID- 26696442
OWN - NLM
STAT- MEDLINE
DCOM- 20170106
LR  - 20170107
IS  - 1533-4023 (Electronic)
IS  - 0160-2446 (Linking)
VI  - 67
IP  - 4
DP  - 2016 Apr
TI  - Effects of Ethyl Pyruvate in Preventing the Development of Diet-induced 
      Atherosclerosis by Blocking the HMGB1 Expression in ApoE-Deficient Mice.
PG  - 299-304
LID - 10.1097/FJC.0000000000000353 [doi]
AB  - Ethyl pyruvate (EP) is a lipid derivative of pyruvate and known as an 
      anti-inflammatory agent effective to inhibit many diseases in experimental 
      models. To test the hypothesis that Ethyl pyruvate might prevent atherosclerosis 
      development by blocking the high-mobility group box-1 (HMGB1) expression, 
      8-week-old ApoE-deficient (ApoE-/-) mice were fed a high-fat diet and treated 
      with EP (50 mg/Kg) or Physiological saline for 12 weeks. THP-1 cells were then 
      differentiated into macrophages by treated with Phorbol-12-myristate-13-acetate 
      (PMA, 100 ng/mL) and incubated with oxidized low-density lipoprotein (oxLDL) only 
      or added with EP (5 mM) for 24 hour. In ApoE-/- mice, EP markedly reduced aortic 
      sinus atherosclerosis lesions with no influence to serum lipid levels. Inhibited 
      HMGB1 expression, decreased macrophages content and reduced Toll-like-receptor2 
      (TLR2), TLR4, monocyte chemotactic protein 1 (MCP-1) and Tumor Necrosis Factor alpha 
      (TNF-alpha) mRNA levels were also observed at the same time. In vitro, EP decreased 
      oxLDL uptake in macrophages and inhibited HMGB1 expression induced by oxLDL. In 
      conclusion, our study indicated that EP was an effective agent against the 
      development of diet-induced atherosclerosis in ApoE-deficient mice by way of 
      blocking the HMGB1 expression.
FAU - Xiao, Hunan
AU  - Xiao H
AD  - Department of Geriatric Cardiology, Chinese People's Liberation Army General 
      Hospital, Beijing, China.
FAU - Liu, Hongbin
AU  - Liu H
FAU - Hou, Congcong
AU  - Hou C
FAU - Liu, Yang
AU  - Liu Y
FAU - Yu, Qian
AU  - Yu Q
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Apolipoproteins E)
RN  - 0 (HMGB1 Protein)
RN  - 0 (Lipids)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Pyruvates)
RN  - 0 (oxidized low density lipoprotein)
RN  - 03O98E01OB (ethyl pyruvate)
RN  - NI40JAQ945 (Tetradecanoylphorbol Acetate)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Apolipoproteins E/*genetics
MH  - Atherosclerosis/etiology/*prevention & control
MH  - Diet, High-Fat
MH  - Gene Expression Regulation/drug effects
MH  - HMGB1 Protein/*genetics
MH  - Lipids/blood
MH  - Lipoproteins, LDL/administration & dosage/metabolism
MH  - Macrophages/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Knockout
MH  - Pyruvates/*pharmacology
MH  - Tetradecanoylphorbol Acetate/pharmacology
EDAT- 2015/12/24 06:00
MHDA- 2017/01/07 06:00
CRDT- 2015/12/24 06:00
PHST- 2015/12/24 06:00 [entrez]
PHST- 2015/12/24 06:00 [pubmed]
PHST- 2017/01/07 06:00 [medline]
AID - 10.1097/FJC.0000000000000353 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2016 Apr;67(4):299-304. doi: 
      10.1097/FJC.0000000000000353.